Amanda Boatright-Scruggs
Payments from drug & device makers
Across 157 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$733
- AbbVie$315
- Amgen$310
- GSK$281
- Novo Nordisk$218
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$195
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,24697%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $733 |
| AbbVie(2 entities) | 17 | $315 |
| Amgen | 16 | $310 |
| GSK | 13 | $281 |
| Novo Nordisk | 7 | $218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $195 |
| Merck | 8 | $159 |
| Bayer | 2 | $141 |
| Corcept Therapeutics | 7 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Astellas Pharma US Inc | 1 | $100 |
| Lilly USA, LLC | 5 | $84 |
| Sanofi-aventis U.S. LLC | 6 | $82 |
| Esperion Therapeutics, Inc. | 5 | $75 |
| Electromed, Inc. | 9 | $71 |
| Novartis | 2 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Johnson & Johnson(2 entities) | 3 | $51 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,346 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 188 | $206,097 |
| EliquisApixaban | 199 | $174,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $80,363 |
| JardianceEmpagliflozin | 56 | $65,364 |
| FarxigaDapagliflozin Propanediol | 71 | $58,357 |
| LinzessLinaclotide | 76 | $55,242 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $53,910 |
| OzempicSemaglutide | 50 | $51,198 |
| TrulicityDulaglutide | 35 | $37,923 |
| TradjentaLinagliptin | 35 | $33,386 |
| JanuviaSitagliptin Phosphate | 35 | $33,334 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $31,854 |
| VraylarCariprazine Hcl | 21 | $30,293 |
| MyrbetriqMirabegron | 53 | $27,422 |
| RybelsusSemaglutide | 26 | $24,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $84 | $244,020223 claims |
| PfizerEliquis | $19 | $174,339199 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $733 | $138,546214 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $24 | $113,133121 claims |
| AbbVieLinzess, Vraylar, Namzaric, Synthroid | $315 | $97,552163 claims |
| GSKTrelegy Ellipta | $281 | $80,363113 claims |
| Novo NordiskOzempic, Rybelsus | $218 | $76,04176 claims |
| MerckJanuvia, Janumet Xr | $159 | $43,99556 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $100 | $34,84168 claims |
| Esperion Therapeutics, Inc.Nexlizet | $75 | $16,14635 claims |
| Johnson & JohnsonXarelto | $51 | $12,94518 claims |
| Sanofi-aventis U.S. LLCLantus | $82 | $3,16924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Alma
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.